Summary Pathogenic bacterial components play critical roles in initiation of gastrointestinal inflammation via activation of intracellular signaling pathways which induce proinflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Lansoprazole (LANSO), a proton pump inhibitor, has been widely used for the treatment of peptic ulcers and reflux esophagitis due to its potent acid-suppressive effect. It has also been reported to have anti-inflammatory effects. In this study we investigated the effects of LANSO on the production of TNF-α and IL-1β induced by lipopolysaccharide (LPS) and Helicobacter pylori water-soluble extract (HpWE) in the human monocytic cell line (THP-1). LANSO (100 μM) significantly reduced mRNA expression and production of TNF-α and IL-1β by THP-1 cells stimulated by LPS and HpWE. LANSO inhibited phosphorylation and degradation of inhibitory factor κB-α (IκB-α) and phosphorylation of extracellular signal-regulated kinase (ERK) induced by LPS and HpWE in THP-1 cells. These findings suggest that LANSO exerts antiinflammatory effects by suppressing induction of TNF-α and IL-1β via inhibition of nuclear factor (NF)-κB and ERK activation.
Introduction
Pathogenic bacteria play crucial roles in the pathophysiology of gastrointestinal inflammation. For instance, Helicobacter pylori (H. pylori) infection is strongly associated with chronic active gastritis [1] [2] [3] . Enterobacteria contribute to the pathogenesis of inflammatory bowel diseases [4] .
Moreover, recent studies suggest that the presence of enterobacteria is essential for the development of nonsteroidal anti-inflammatory drugs (NSAIDs)-induced small intestinal injury [5] [6] [7] .
In the process of gastrointestinal inflammation triggered by bacteria, binding of bacterial components to receptors on the surface of effector cells including monocytes/macrophages is a critical initial step [8] . Proinflammatory responses initiated by bacteria are elicited by the interaction of bacterial components with Toll-like receptors (TLRs) expressed on monocytes/macrophages [9] . For example, lipopolysaccharide (LPS), derived from outer membrane of Gram-negative bacteria, binds to TLR4, and signaling by it leads to activation of nuclear factor (NF)-κB and mitogenactivated protein kinase (MAPK) signaling pathways, which subsequently induce a variety of genes involved in inflammatory responses such as tumor necrosis factor (TNF)-α and interleukin(IL)-1β. It also appears that H. pylori stimulates TLR, although the subtype responsible for this remains controversial [10, 11] . These intracellular signaling pathways from receptors to the nucleus could be a therapeutic target for prevention and regulation of deleterious inflammatory responses which may lead to progression of disease or impairment of gastrointestinal physiological function.
Lansoprazole (LANSO), a proton pump inhibitor, has been widely used for the treatment of peptic ulcers and reflux esophagitis due to its potent acid-suppressive effects mediated via inhibition of p-type H + K + -adenosine triphosphatase. LANSO has also been reported to have antiinflammatory effects [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, the precise mechanism of its anti-inflammatory effects remains unclear.
In this study, we investigated the effects of LANSO on LPS-or H. pylori-induced production of TNF-α and IL-1β by the human monocytic cell line THP-1 and attempted to elucidate the underlying anti-inflammatory mechanism of LANSO.
Materials and Methods

Materials
LPS (Escherichia coli O55:B5), pyrrolidinedithiocarbamate (PDTC), an inhibitor of NF-κB activation, and PD98059, a MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor, were purchased from Sigma (St. Louis, MO). Antibody to inhibitory factor κB-α (IκB-α) and phosphorylated IκB-α was purchased from Cell Signaling Technology (Danvers, MA), and antibody for ERK2 and phosphorylated ERK2 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). LANSO was a gift from Takeda Pharmaceuticals (Osaka, Japan).
Preparation of H. pylori water-soluble extract (HpWE) H. pylori (ATCC 43505 strain, cag A+ and vac A+) was grown to a concentration of 2.0 × 10 8 colony-forming units (CFUs)/ml in Brucella broth (BBL, Cockeysville, MD) containing 10% sterile heat-inactivated horse serum. The flasks were incubated at 37°C for 24 h under microaerophilic conditions with agitation on a rotary shaker at 160 rpm. After centrifugation of H. pylori-containing broth culture at 8300 rpm for 20 min at 4°C, supernatant was discarded and cold PBS was added to the tube. After washing the bacterial pellet with gentle inversion, the bacterial suspension was centrifuged at 8300 rpm for 10 min at 4°C. This washing procedure was repeated three times, and finally the cell suspension was sonicated for 30 s. The suspension was then centrifuged at 14000 rpm for 30 min at 4°C. The supernatant was then passed through a 0.22 μm filter unit (Nihon Millipore KK, Tokyo, Japan). This procedure removes much of the high-molecular-weight complex material, which mainly consists of membrane vesicles and intact flagella. Filtered supernatant was stored at −80°C until experimentation.
Cell culture
THP-1 was purchased from American Type Culture Collection (Manassas, VA). Cells were routinely maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. LPS (10 ng/mL) or HpWE (5 μg/ml) was added and incubated for up to 3 h with or without preincubation with LANSO (100 μM) dissolved in dimethyl sulfoxide (DMSO) for 3 h. In another series of experiments, cells were pretreated with 100 μM of PDTC or 10 μM or PD98059 for 30 min and LPS or HpWE was added and incubated for 3 h.
Enzyme-linked Immunosorbent Assay (ELISA)
Cell culture supernatant was collected and production of TNF-α and IL-1β was determined using a commercial ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
Determination of expression of mRNA for TNF-α and IL-1β by real-time quantitative RT-PCR
Total RNA was isolated using an ISOGEN kit (Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol. PCR primers and TaqMan probes for TNF-α and IL-1β were designed using Primer Express, a software program (PE Applied Biosystems, Foster City, CA). TaqMan probes were labeled with a reporter fluorescent dye (6-carboxyfluorescein) at the 5' end and a fluorescent dye quencher (6-carboxytetramethylrhodamine) at the 3' end. For TNF-α, the sense primer was 5-TCATGCACCACCAT-CAAGGA-3, the antisense primer was 5-GAGGCAACCT-GACCACTCTCC-3, and the TaqMan probe was 5-AATGGGCTTTCCGAATTCACTGGAGC-3. For IL-1β, the sense primer was 5-ACAGGCTCCGAGATGAACAAC-3, the antisense primer was 5-CCATTGAGGTGGAGA-GCTTTC-3, and the TaqMan probe was 5-AAAAAGC-CTCGTGCTGTCGGACCCATAT-3. Real-time quantitative RT-PCR analyses were performed using an ABI PRISM 7700 Sequence Detection System instrument and software (PE Applied Biosystems). The reaction mixture was prepared according to the manufacturer's protocol using the Platinum qRT-PCR ThermoScript One-Step System (Invitrogen, Carlsbad, CA). Thermal cycling conditions comprised 50°C for 30 min and 95°C for 5 min, followed by 45 cycles of amplification at 95°C for 15 s and 60°C for 1 min. Total RNA was subjected to real-time quantitative RT-PCR for measurement of target genes and GAPDH as an internal standard using TaqMan GAPDH control reagents (PE Applied Biosystems). Expression of mRNA for TNF-α and IL-1β was standardized to GAPDH mRNA and mRNA levels were expressed as ratios to the mean value for vehicle (DMSO)-treated control cells.
Western blot analysis
Cells were homogenized and lysed on ice in a buffer containing 0.5% NP-40, 40 mM Tris HCl (pH 8.0), 120 mM NaCl and a protease inhibitor cocktail (Complete Mini, Pierce, Rockford, IL). Protein in the lysate was measured with a modified bicinchoninic acid method (Pierce, Rockford, IL). Proteins were denatured with SDS sample buffer, subjected to SDS-polyacrylamide gel electrophoresis, and transferred to a PVDF membrane. Membranes were blocked in TBS buffer containing 5% skim milk and were then incubated overnight with antibodies to IκB-α, phosphorylated IκB-α, phosphorylated ERK, or ERK2. The bound antigen-antibody complexes were detected with anti-rabbit or mouse IgG-HRP, using enhanced chemiluminescence in accordance with the manufacturer's instructions (Amersham, Arlington Heights, IL).
Statistical Analysis
Values are the mean ± SD. One-way analysis of variance was used to test for significance of differences among treatment group means, and results were examined by Fisher's protected least-significant-difference test. Differences with p values less than 0.05 were considered significant.
Results
LANSO inhibits LPS-induced TNF-α and IL-1β gene expression and protein production
Although unstimulated THP-1 cells constitutively express mRNA for TNF-α and IL-1β, production of TNF-α and IL-1β protein was not detected in culture supernatant in which THP-1 cells were grown for 6 h by ELISA because of the sensitivity of the experimental system used in the present study. LPS increased expression of mRNA for TNF-α by 176-fold after one-hr and by 185-fold after two-hr incubation with LPS. Similar to TNF-α, LPS induced expression of mRNA for IL-1β by 319-fold after one-hr and 802-fold after two-hr incubation with LPS. LPS induced protein production of TNF-α and IL-1β after 3 h of incubation with LPS. Pretreatment with 100 μM of LANSO for 3 h decreased LPS-induced expression of mRNA for TNF-α by 57% and protein production of TNF-α protein by 51%. LPS also inhibited expression of mRNA for IL-1β by 62% and protein production of IL-1β by 71% (Fig. 1) .
LANSO inhibits HpWE-induced TNF-α and IL-1β gene expression and protein production
HpWE increased expression of mRNA for TNF-α by 48-fold after two-hr incubation with HpWE. Similar to TNF-α, HpWE induced expression of mRNA for IL-1β by 200-fold after two-hr incubation with HpWE. HpWE induced protein production of TNF-α and IL-1β after 3 h of incubation with HpWE. Pretreatment with 100 μM LANSO for 3 h decreased HpWE-induced expression of mRNA for TNF-α by 27% and protein production of TNF-α by 48%. LPS also inhibited expression of mRNA for IL-1β by 50% and protein production of IL-1β by 93% (Fig. 2) .
Inhibition of NF-κB and ERK decreases LPS-induced production of TNF-α in THP-1 cells
To confirm the relevance of NF-κB and ERK to production of TNF-α by THP-1 cells stimulated by LPS, we examined the effects of PDTC, an inhibitor of NF-κB activation, and PD 98059, a MEK inhibitor. Pretreatment with PDTC or PD98059 decreased the protein production of TNF-α by THP-1 cells stimulated by LPS (Fig. 3 ) by 54% and 34%, respectively. These findings indicate that activation of NF-κB and ERK is responsible for production of TNF-α by THP-1 cells stimulated by LPS (Fig. 3) .
LANSO inhibits LPS-induced phosphorylation and degradation of IκB-α and phosphorylation of ERK
Stimulation with LPS for one hr induced phosphorylation and degradation of IκB-α and phosphorylation of ERK. Pretreatment with LANSO for one hr inhibited LPS-induced phosphorylation and degradation of IκB-α and phosphorylation of ERK (Fig. 4) .
LANSO inhibits HpWE-induced phosphorylation and degradation of IκB-α and phosphorylation of ERK
Similar to LPS, stimulation with HpWE for one hr induced phosphorylation and degradation of IκB-α and phosphorylation of ERK. Pretreatment with LANSO for one hr inhibited HpWE-induced phosphorylation and degradation of IκB-α and phosphorylation of ERK (Fig. 5) .
Discussion
In the present study, we demonstrated that LANSO inhibits LPS and HpWE-induced transcription and production of TNF-α and IL-1β. We also showed that LANSO inhibited activation of NF-κB and ERK induced by LPS and HpWE, which could account for why LANSO exerts antiinflammatory effects.
Production of proinflammatory cytokines such as TNF-α and IL-1β by inflammatory cells is one of the pivotal processes in gastrointestinal inflammation. In response to interaction with pathogenic bacteria, inflammatory cells produce proinflammatory cytokines, which activate further inflammatory processes and promote inflammation. In the present study, we showed that LANSO inhibits production of TNF-α and IL-1β by the monocytic cell line THP-1 stimulated by LPS or HpWE. Moreover, Nakamura et al. reported that uptake of LANSO was observed in inflammatory cells including polymorphonuclear cells and macrophages in the colonic mucosa of rats with dextran sodium sulfate-induced colitis [23] . These findings suggest that LANSO may exert anti-inflammatory effects in gastrointestinal inflammation via suppression of production of proinflammatory cytokines from inflammatory cells stimulated by pathogenic bacteria.
Several reports have suggested mechanisms by which LANSO and other proton pump inhibitors exert antiinflammatory effects [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . In the present study, we focused on the NF-κB and ERK signaling pathways, since they are important transcription factors of critical importance for induction of production of proinflammatory cytokines by monocytes stimulated by LPS [24] [25] [26] or HpWE [27] . Our study demonstrated that the suppression of TNF-α and IL-1β induced by LPS and HpWE was accompanied by inhibition of phosphorylation and degradation of IκB-α and phosphorylation of ERK. These findings suggest that the inhibitory effect of LANSO on expression of TNF-α and IL-1β by THP-1 cells stimulated by LPS and HpWE was associated with inhibition of the NF-κB or ERK signaling pathway via inhibition of phosphorylation and degradation of IκB-α and phosphorylation of ERK. The precise mechanism by which LANSO inhibits activation of NF-κB and ERK remains unknown. LPS and HpWE act as ligands of TLRs, and both NF-κB and ERK are downstream signaling molecules of the TLRs-signaling pathway [9] [10] [11] . Taken together, these findings suggest the possibility that LANSO suppresses phosphorylation and degradation of IκB-α and phosphorylation of ERK via inhibition of the TLR signaling pathway.
In summary, the present findings highlight the novel antiinflammatory effects of LANSO. LANSO suppressed production of the proinflammatory cytokines TNF-α and IL-1β by human monocytic cells stimulated by representative pathogenic bacterial components in the gastrointestinal tract, LPS and HpWE. LANSO is already clinically used for peptic ulcer disease and reflux esophagitis, and it appears possible to extend its clinical application to control of inflammation of the gastrointestinal tract caused by pathogenic bacteria in conditions such as inflammatory bowel disease, chronic active gastritis, and NSAID-induced gastrointestinal injury.
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